MedTrace Logo

Fenofibrate and Propranolol in Burn Patients

NCT02452255 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2019-11-29

No results posted yet for this study

Summary

The proposed study will test the hypothesis that Propranolol, fenofibrate and fenofibrate plus propranolol have therapeutic, physiological, and metabolic effects that will improve clinical outcomes, and the long-term recovery, rehabilitation, and QOL in burned patients.

Conditions

  • Burn

Interventions

DRUG

Fenofibrate

Fenofibrate by mouth given daily throughout hospitalization for up to 12 months

DRUG

Placebo

Placebo by mouth given daily throughout hospitalization for up to 12 months

DRUG

Propranolol

Propranolol by mouth given daily throughout hospitalization for up to 12 months

Sponsors & Collaborators

  • National Institute of General Medical Sciences (NIGMS)

    collaborator NIH

  • Shriners Hospitals for Children

    collaborator OTHER

  • The University of Texas Medical Branch, Galveston

    lead OTHER

Principal Investigators

  • David N Herndon, MD · University of Texas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2018-12-31
Completion
2019-07-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02452255 on ClinicalTrials.gov